KCP-506

**KCP-506** is a first-in-class, non-opioid **α9α10 nicotinic acetylcholine receptor (nAChR) antagonist** developed by Kineta (now TuHURA Biosciences) in collaboration with Genentech for **chronic neuropathic pain**. It demonstrates robust **analgesic, anti-neuroinflammatory, and neuroprotective effects** in preclinical models without central nervous system side effects or addiction potential, as the target is not expressed in the CNS. Administered via **intravenous (IV) and subcutaneous (SC)** routes, it advanced to **Phase 1 clinical trials** (completed single and multiple ascending dose studies in healthy volunteers by 2021) evaluating safety, tolerability, and pharmacokinetics, with potential applications in **diabetic neuropathy, radiculopathy, and chemotherapy-induced peripheral neuropathy**.[1][4][6][11]